| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Neuro-Oncology [T. S., H. L., X. C., D. K., Y-K. H., W. K. A. Y., P. A. S.], Neuropathology [L. A. L.], Epidemiology [M. L. B.], Biomathematics [K. R. H.], and Head and Neck Surgery [J. N. M.], The Brain Tumor Center, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
MMAC/PTEN, a tumor suppressor gene located on chromosome 10q, has recently been shown to act as a phosphatidylinositol 3,4,5-triphosphate phosphatase and to modulate cell growth and apoptosis. Somatic mutations of MMAC/PTEN have been reported in a number of human cancers, especially in glioblastoma multiforme (GBM), although the number of identified mutations (
10–35%) is significantly lower than the frequency of LOH affecting the MMAC/PTEN locus in the specimens (75–95%). To further investigate the possible alterations that may affect MMAC/PTEN, we examined the expression of the gene by reverse transcription-PCR in a series of gliomas. A significant difference (P < 0.001) was observed between the expression of MMAC/PTEN in GBMs versus lower grades of gliomas, thus mimicking the difference in allelic deletion associated with the locus in these tumors. Furthermore, Kaplan-Meier survival plots, adjusted for age and tumor grade, showed a significantly better prognosis for patients whose tumors expressed high levels of MMAC/PTEN. Additionally, immunostaining of GBMs revealed little or no MMAC/PTEN expression in about two-thirds of the tumors, whereas the other approximately one-third of tumors had significantly higher levels of expression. However, in about two-thirds of the high-expressing specimens, a heterogeneous pattern of expression was observed, indicating that certain cells within the tumor failed to express MMAC/PTEN. The combination of these results suggest that, in addition to molecular alterations affecting the gene, altered expression of MMAC/PTEN may play a significant role in the progression of GBM and patient outcome.
This article has been cited by other articles:
|
|
 |
|
  S. M. Planchon, K. A. Waite, and C. Eng The nuclear affairs of PTEN J. Cell Sci., February 1, 2008; 121(3): 249 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y.C. Chow, K. T. Quach, B. L. Cabrera, J. A. Cabral, S. E. Beck, and J. M. Carethers RAS/ERK modulates TGF{beta}-regulated PTEN expression in human pancreatic adenocarcinoma cells Carcinogenesis, November 1, 2007; 28(11): 2321 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Dunlap, J. Celestino, H. Wang, R. Jiang, E. C. Holland, G. N. Fuller, and W. Zhang Insulin-like growth factor binding protein 2 promotes glioma development and progression PNAS, July 10, 2007; 104(28): 11736 - 11741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Wiencke, S. Zheng, N. Jelluma, T. Tihan, S. Vandenberg, T. Tamguney, R. Baumber, R. Parsons, K. R. Lamborn, M. S. Berger, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma Neuro-oncol, July 1, 2007; 9(3): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M.P. Omuro, S. Faivre, and E. Raymond Lessons learned in the development of targeted therapy for malignant gliomas Mol. Cancer Ther., July 1, 2007; 6(7): 1909 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wrensch, T. Rice, R. Miike, A. McMillan, K. R. Lamborn, K. Aldape, and M. D. Prados Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area Neuro-oncol, January 1, 2006; 8(1): 12 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Zhou, K. R. Hess, L. Liu, Mark. E. Linskey, and W.K. A. Yung Modeling prognosis for patients with malignant astrocytic gliomas: Quantifying the expression of multiple genetic markers and clinical variables Neuro-oncol, October 1, 2005; 7(4): 485 - 494. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Misra, M. Pellarin, J. Nigro, I. Smirnov, D. Moore, K. R. Lamborn, D. Pinkel, D. G. Albertson, and B. G. Feuerstein Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma Clin. Cancer Res., April 15, 2005; 11(8): 2907 - 2918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Leuraud, L. Taillandier, J. Medioni, L. Aguirre-Cruz, E. Criniere, Y. Marie, M. Kujas, J.-L. Golmard, A. Duprez, J.-Y. Delattre, et al. Distinct Responses of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic Alterations Cancer Res., July 1, 2004; 64(13): 4648 - 4653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Zhou, F. Tan, K. R. Hess, and W. K. A. Yung The Expression of PAX6, PTEN, Vascular Endothelial Growth Factor, and Epidermal Growth Factor Receptor in Gliomas: Relationship to Tumor Grade and Survival Clin. Cancer Res., August 1, 2003; 9(9): 3369 - 3375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Lang, M. R. Gilbert, V. K. Puduvalli, J. Weinberg, V. A. Levin, W.K. A. Yung, R. Sawaya, G. N. Fuller, and C. A. Conrad Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies Neuro-oncol, October 1, 2002; 4(4): 268 - 277. [Abstract] [PDF]
|
|
|
|
|
|
C. B. Knobbe, A. Merlo, and G. Reifenberger Pten signaling in gliomas Neuro-oncol, July 1, 2002; 4(3): 196 - 211. [Abstract] [PDF]
|
|
|
|
|
|
R. P. Ermoian, C. S. Furniss, K. R. Lamborn, D. Basila, M. S. Berger, A. R. Gottschalk, M. K. Nicholas, D. Stokoe, and D. A. Haas-Kogan Dysregulation of PTEN and Protein Kinase B Is Associated with Glioma Histology and Patient Survival Clin. Cancer Res., May 1, 2002; 8(5): 1100 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Minaguchi, H. Yoshikawa, K. Oda, T. Ishino, T. Yasugi, T. Onda, S. Nakagawa, K. Matsumoto, K. Kawana, and Y. Taketani PTEN Mutation Located Only Outside Exons 5, 6, and 7 Is an Independent Predictor of Favorable Survival in Endometrial Carcinomas Clin. Cancer Res., September 1, 2001; 7(9): 2636 - 2642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Smith, I. Tachibana, S. M. Passe, B. K. Huntley, T. J. Borell, N. Iturria, J. R. O'Fallon, P. L. Schaefer, B. W. Scheithauer, C. D. James, et al. PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme J Natl Cancer Inst, August 15, 2001; 93(16): 1246 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sasaki, M. C. Zlatescu, R. A. Betensky, Y. Ino, J. G. Cairncross, and D. N. Louis PTEN Is a Target of Chromosome 10q Loss in Anaplastic Oligodendrogliomas and PTEN Alterations Are Associated with Poor Prognosis Am. J. Pathol., July 1, 2001; 159(1): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Maher, F. B. Furnari, R. M. Bachoo, D. H. Rowitch, D. N. Louis, W. K. Cavenee, and R. A. DePinho Malignant glioma: genetics and biology of a grave matter Genes & Dev., June 1, 2001; 15(11): 1311 - 1333. [Full Text] [PDF]
|
|
|
|
|
|
K. Kurose, X.-P. Zhou, T. Araki, S. A. Cannistra, E. R. Maher, and C. Eng Frequent Loss of PTEN Expression Is Linked to Elevated Phosphorylated Akt Levels, but Not Associated with p27 and Cyclin D1 Expression, in Primary Epithelial Ovarian Carcinomas Am. J. Pathol., June 1, 2001; 158(6): 2097 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fults and C. Pedone Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas Neuro-oncol, April 1, 2000; 2(2): 71 - 79. [Abstract] [PDF]
|
|
|
|
|
|
J. W. Gray and C. Collins Genome changes and gene expression in human solid tumors Carcinogenesis, March 1, 2000; 21(3): 443 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhang and B. M. Steinberg Overexpression of PTEN/MMAC1 and Decreased Activation of Akt in Human Papillomavirus-infected Laryngeal Papillomas Cancer Res., March 1, 2000; 60(5): 1457 - 1462. [Abstract] [Full Text]
|
|
|
|
|
|
M. E. McMenamin, P. Soung, S. Perera, I. Kaplan, M. Loda, and W. R. Sellers Loss of PTEN Expression in Paraffin-embedded Primary Prostate Cancer Correlates with High Gleason Score and Advanced Stage Cancer Res., September 1, 1999; 59(17): 4291 - 4296. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
